ES2109924T3 - Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas. - Google Patents

Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.

Info

Publication number
ES2109924T3
ES2109924T3 ES90910982T ES90910982T ES2109924T3 ES 2109924 T3 ES2109924 T3 ES 2109924T3 ES 90910982 T ES90910982 T ES 90910982T ES 90910982 T ES90910982 T ES 90910982T ES 2109924 T3 ES2109924 T3 ES 2109924T3
Authority
ES
Spain
Prior art keywords
versatile
cells
eucarytic
genes
rapid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90910982T
Other languages
English (en)
Inventor
Bernard Moss
Thomas Fuerst
Orna Elroy-Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2109924T3 publication Critical patent/ES2109924T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12N9/1033—Chloramphenicol O-acetyltransferase (2.3.1.28)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE HA DESCRITO UN SISTEMA DE EXPRESION EFICAZ, VERSATIL Y SENCILLO QUE OTORGA UNA EXPRESION INDEPENDIENTE DE LA CUBIERTA A LOS ARN PROCARIOTICOS EN CELULAS EUCARIOTICAS. SE HA PRESENTADO LA UTILIDAD DEL VIRUS DE LA VACUNA RECOMBINANTE PARA ESTE PROPOSITO.
ES90910982T 1989-07-07 1990-07-03 Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas. Expired - Lifetime ES2109924T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/376,687 US5135855A (en) 1986-09-03 1989-07-07 Rapid, versatile and simple system for expressing genes in eukaryotic cells

Publications (1)

Publication Number Publication Date
ES2109924T3 true ES2109924T3 (es) 1998-02-01

Family

ID=23486043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90910982T Expired - Lifetime ES2109924T3 (es) 1989-07-07 1990-07-03 Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.

Country Status (9)

Country Link
US (1) US5135855A (es)
EP (1) EP0484374B1 (es)
JP (1) JP2525289B2 (es)
AT (1) ATE157701T1 (es)
AU (1) AU642657B2 (es)
CA (1) CA2063427C (es)
DE (1) DE69031389T2 (es)
ES (1) ES2109924T3 (es)
WO (1) WO1991000905A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
WO1993017117A1 (en) 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
IL102404A0 (en) * 1992-07-03 1993-01-14 Daniel Zurr Method and means for the production of gene products
US5648235A (en) * 1992-07-03 1997-07-15 Q.B.I. Enterprises Ltd. Method and means for the production of gene products, novel recombinant DNA vectors therefor and kits employing them
US5409823A (en) * 1992-09-24 1995-04-25 Ciba-Geigy Corporation Methods for the production of hybrid seed
WO1994023745A1 (en) * 1993-04-09 1994-10-27 The University Of Virginia Patents Foundation 35/31 kda subunit of the entamoeba histolytica adherence lectin
US5591601A (en) * 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
CA2191362A1 (en) 1994-06-02 1995-12-14 Mark Selby Nucleic acid immunization using a virus-based infection/transfection system
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5994526A (en) * 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
AU725002B2 (en) * 1996-06-21 2000-10-05 Plant Genetic Systems N.V. Gene expression in plants
AU722624B2 (en) * 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
WO1999018221A1 (en) * 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
US20020012971A1 (en) * 2000-03-20 2002-01-31 Mehta Tammy Burd PCR compatible nucleic acid sieving medium
GB2362383B (en) * 2000-05-19 2003-12-31 Devgen Nv Gene expression system
US20030021766A1 (en) 2001-01-12 2003-01-30 Michael Vajdy Nucleic acid mucosal immunization
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
DE102006015321A1 (de) * 2006-03-30 2007-10-04 Rina-Netzwerk Rna Technologien Gmbh Verfahren zur Genexpression
CN105056229A (zh) * 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN108348593B (zh) 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2023070072A1 (en) 2021-10-21 2023-04-27 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Retroelement-generated transcription factor decoys
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183588A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) * 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
AU4507589A (en) * 1988-10-11 1990-05-01 United States of America, as represented by the Secretary, U.S. Department of Commerce, The New plasmid constructions for high level production of eukaryotic proteins

Also Published As

Publication number Publication date
JPH05501048A (ja) 1993-03-04
US5135855A (en) 1992-08-04
DE69031389D1 (de) 1997-10-09
EP0484374B1 (en) 1997-09-03
AU642657B2 (en) 1993-10-28
AU6034490A (en) 1991-02-06
DE69031389T2 (de) 1998-03-19
EP0484374A4 (en) 1993-05-05
JP2525289B2 (ja) 1996-08-14
CA2063427A1 (en) 1991-01-08
ATE157701T1 (de) 1997-09-15
WO1991000905A1 (en) 1991-01-24
EP0484374A1 (en) 1992-05-13
CA2063427C (en) 1999-09-21

Similar Documents

Publication Publication Date Title
ES2109924T3 (es) Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DK198883D0 (da) Fremgangsmade til fremstilling af menneskevaevs-plasminogenaktivator, dna-sekvens der koder for denne aktivator, replicerbar udtrykkelsesvektor for dna-sekvensen og microorganisme eller cellekultur transformeret med udtrykkelsesvektoren
DK592186D0 (da) Fremgangsmaade til udvinding af proteiner
ES2056817T3 (es) Transformacion de trichoderma.
HK1075467A1 (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
NO965627D0 (no) Nytt cytokin betegnet lerk-5
ATE140968T1 (de) Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
ATE312188T1 (de) Lokalisierung von therapeutischen mitteln
DK0799058T3 (da) Forbedringer af eller med hensyn til endometriefunktion
DE3650135D1 (de) Proteingewinnung.
TW224968B (es)
NZ304570A (en) Neurone-restrictive silencer factor proteins, nucleic acids and antibodies thereto
FI854395A (fi) Sv40-expressionsvektor innehaollande hbxag-antigen som expressionsmarkering.
ATE326537T1 (de) Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
DK35483A (da) Expressionsvectorer for catechol-2,3-oxygenase, de vundne enzymer og deres anvendelse
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
EP0227604A3 (en) Use of oligopeptides in the treatment of viral infections
FI924494A0 (fi) Oekad produktion av avsoendrarde proteiner i eukaryotiska rekombinantceller
DE60026666D1 (de) Induktion von antigen-spezifischen T-Zellen durch Interferon
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
IT1176081B (it) Metodo per la terminazione di polimeri viventi e composti adatti allo scopo
AT375962B (de) Kathodeneinrichtung, insbesondere zur durchfuehrung von chloralkalielektrolysen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 484374

Country of ref document: ES